Two small molecule EGFR tyrosine kinase inhibitors have been developed, erlotinib (Tarceva®, OSI-774, Genentech, Inc, CA, USA) and gefitinib (Iressa®, ZD1839, AstraZeneca, DE, USA) that have been evaluated for GBM treatment, Table 1. Here, EGFR is linked to glioblastoma.